Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Reports No Revenues, $164K Loss for Q1

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic test development firm Med BioGene today reported a loss of C$159,164 ($163,877), or C$.00 on a per-share basis, for the first quarter with no revenues.

The Vancouver, British Columbia-based company also had no revenues for the first quarter of 2010, when it posted a loss of C$453,874, or $.01 per share.

During the three months ended March 31, Med BioGene's R&D expenses declined to C$42,421, compared to C$131,568 a year ago. Its SG&A spending also was reduced to C$106,998 from C$303,828 a year ago.

The company ended the quarter with cash and cash equivalents of C$89,493.

In April the firm forged an agreement with Precision Therapeutics for the exclusive global development and commercialization rights to Med BioGene's LungExpress Dx test for non-small cell lung cancer. The deal calls for Precision to pay Med BioGene $2.3 million in licensing fees and research reimbursements within 120 days of closing the deal. Med BioGene is also eligible for royalty payments.

In May it closed on a private placement which brought in gross proceeds of C$210,000.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.